Search Results - "Richman, S.D"

6125 Topoisomerase-1 (Topo1) as a predictive and prognostic factor in colorectal cancer chemotherapy by Richman, S.D, Thompson, L.C, Quirke, P, Langley, R.E, Wasan, H.S, Daly, C, Parmar, M.K.B, Kaplan, R, Seymour, M.T

Get full text

337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials by Hassanieh, S., Domingo, E., Blake, A., Fisher, D., Redmond, K.L., Richman, S.D., Walker, S.M., Quirke, P., Wilson, R.H., Kennedy, R., Tomlinson, I., Kaplan, R.S., L. brown, Dunne, P., Seymour, M.T., Morton, D., Adams, R.A., West, N., Maughan, T.

Get full text

Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application by Echle, A., Ghaffari Laleh, N., Quirke, P., Grabsch, H.I., Muti, H.S., Saldanha, O.L., Brockmoeller, S.F., van den Brandt, P.A., Hutchins, G.G.A., Richman, S.D., Horisberger, K., Galata, C., Ebert, M.P., Eckardt, M., Boutros, M., Horst, D., Reissfelder, C., Alwers, E., Brinker, T.J., Langer, R., Jenniskens, J.C.A., Offermans, K., Mueller, W., Gray, R., Gruber, S.B., Greenson, J.K., Rennert, G., Bonner, J.D., Schmolze, D., Chang-Claude, J., Brenner, H., Trautwein, C., Boor, P., Jaeger, D., Gaisa, N.T., Hoffmeister, M., West, N.P., Kather, J.N.

“…Microsatellite instability (MSI)/mismatch repair deficiency (dMMR) is a key genetic feature which should be tested in every patient with colorectal cancer…”
Get full text

Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials by Seligmann, J.F., Fisher, D., Smith, C.G., Richman, S.D., Elliott, F., Brown, S., Adams, R., Maughan, T., Quirke, P., Cheadle, J., Seymour, M., Middleton, G.

“…To improve strategies for the treatment ofBRAF-mutant advanced colorectal cancer (aCRC) patients, we examined individual data from patients treated with…”
Get full text

553PTHE DERIVED NEUTROPHIL LYMPHOCYTE RATIO (DNLR) AS A BIOMARKER IN ADVANCED COLORECTAL CANCER (ACRC) by Seligmann, J.F., Hall, P., Wilson, H., Richman, S.D., Barrett, J., Seymour, M., Quirke, P.

“…Abstract Aim: Links between inflammation, the immune response and cancer outcomes are compelling. The dNLR, calculated from a standard blood count, is a simple…”
Get full text

Primary Tumour Location (Ptl) As a Prognostic and Predictive Factor in Advanced Colorectal Cancer (Acrc): Data from 2075 Patients (Pts) in Randomised Trials by Seligmann, J.F., Elliott, F., Richman, S.D., Southward, K., Barrett, J., Quirke, P., Seymour, M.

Get full text

The Derived Neutrophil Lymphocyte Ratio (Dnlr) As a Biomarker in Advanced Colorectal Cancer (Acrc) by Seligmann, J.F., Hall, P., Wilson, H., Richman, S.D., Barrett, J., Seymour, M., Quirke, P.

Get full text

509PDPRIMARY TUMOUR LOCATION (PTL) AS A PROGNOSTIC AND PREDICTIVE FACTOR IN ADVANCED COLORECTAL CANCER (ACRC): DATA FROM 2075 PATIENTS (PTS) IN RANDOMISED TRIALS by Seligmann, J.F., Elliott, F., Richman, S.D., Southward, K., Barrett, J., Quirke, P., Seymour, M.

“…Abstract Aim: Variations in tumour biology and outcomes depending upon PTL have been reported in aCRC. We tested effects of PTL in two phase III randomised…”
Get full text

Deficient Mismatch Repair (DMMR) and Braf Mutation (MT) Status in Patients (PTS) With Metastatic Colorectal Cancer (MCRC): A Meta-Analysis of the Cairo, CAIRO2, Coin and Focus Studies by Venderbosch, S., De Haan, T., Heideman, D.A.M., Maughan, T.S., Smith, C.G., Quirke, P., Richman, S.D., Nagtegaal, I.D., Punt, C.J.A., Koopman, M.

Get full text

521O - Deficient Mismatch Repair (DMMR) and Braf Mutation (MT) Status in Patients (PTS) With Metastatic Colorectal Cancer (MCRC): A Meta-Analysis of the Cairo, CAIRO2, Coin and Focus Studies by Venderbosch, S., De Haan, T., Heideman, D.A.M., Maughan, T.S., Smith, C.G., Quirke, P., Richman, S.D., Nagtegaal, I.D., Punt, C.J.A., Koopman, M.

“…In stage II-III CRC the overall incidence of BRAF mt and dMMR is 8% and 10-20%, resp. The incidence of BRAF mt in sporadic dMMR is high (24%, Roth et al., JCO…”
Get full text

What can the molecular pathologist offer for optimal decision making? by Richman, S. D., Hutchins, G. G. A., Seymour, M. T., Quirke, P.

“…As a consequence of new innovative therapies and therapeutic combinations, the treatment of advanced colorectal cancer is becoming increasingly complex…”
Get full text

Radionuclide studies in Hodgkin's disease and lymphomas by Richman, S D, Levenson, S M, Jones, A E, Johnston, G S

“…A rational, multidisciplinary approach to Hodgkin's disease and the non-Hodgkin's lymphomas has been responsible for major advances in therapy. Invasive…”
Get more information